Key result
The presence of subclinical atheroma plaque significantly increased the risk of cardiovascular events (HR 2.50), and quantifying the number of affected arterial territories further improved risk prediction.
Why the study?
Does assessing the extent of subclinical atheromatosis (number of territories with plaque) improve the prediction of cardiovascular events compared to mere plaque presence in patients with chronic kidney disease?
Cohort (n=3,004)
Yes
Does assessing the extent of subclinical atheromatosis (number of territories with plaque) improve the prediction of cardiovascular events compared to mere plaque presence in patients with chronic kidney disease?
Hazard Ratio: 2.5 (95% CI 1.5–4.17)
p-value: p=<0.001
Quantifying the extent of subclinical atheromatosis across multiple arterial territories improves cardiovascular risk prediction in non-dialysis CKD patients compared to merely detecting plaque presence.
Patients with chronic kidney disease (CKD) have an increased incidence of cardiovascular events (CVE). The contribution of subclinical atheromatosis extent, including femoral arteries, to CVE in CKD patients has not been investigated. In this paper, we examine the prognostic value of subclinical atheromatosis extent, assessed as the number of arterial territories with plaque, in predicting the incidence of major and minor CVE. The NEFRONA is a multicenter, prospective cohorts study that recruited 2445 CKD subjects and 559 controls, free from previous cardiovascular disease, in 81 medical centers across Spain. The presence of atheroma plaque was assessed by arterial ultrasound in ten arterial territories (carotid and femoral). The predictive power of the presence or absence of atheroma plaque in any territory was compared with the quantification of atheroma extent as the number of territories with plaque. During the median follow up of 48 months, 216 CVE were reported. Factors predicting the incidence of CVE in the whole cohort were being male, CKD patient, lower levels of 25(OH) vitamin D, higher levels of cholesterol and the extent of subclinical atheromatosis, yielding a higher concordance (C) index than the presence or absence of plaque. In stratified analysis including specific factors of CKD patients not on dialysis, the variables predicting CVE were the same as in the whole cohort, plus higher levels of potassium. Again, the inclusion of the information about atheromatosis as number of territories with plaque, presented a higher C index than the presence or absence of plaque. In the dialysis population, significant variables were older age, diabetes, dialysis vintage and higher levels of cholesterol and phosphate. In this case the higher C index was obtained with the information about plaque presence. Subclinical atheromatosis extent, including femoral arteries, influences CVE in CKD and its detection could improve the prediction of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Valdivielso et al. (2017) conducted a cohort in Chronic kidney disease (n=3,004). Subclinical atheromatosis vs. Absence of atheroma plaque was evaluated on Incidence of cardiovascular events (CVE) (HR 2.50, 95% CI 1.50-4.17, p=<0.001). The presence of subclinical atheroma plaque significantly increased the risk of cardiovascular events (HR 2.50), and quantifying the number of affected arterial territories further improved risk prediction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: